Revolution Medicines, Inc. $RVMD Shares Bought by Candriam S.C.A.

Candriam S.C.A. raised its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 20.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 868,724 shares of the company’s stock after acquiring an additional 149,211 shares during the quarter. Candriam S.C.A. owned approximately 0.46% of Revolution Medicines worth $40,569,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Nextech Invest Ltd. boosted its holdings in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Millennium Management LLC grew its position in Revolution Medicines by 681.8% in the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after acquiring an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Revolution Medicines by 14.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Revolution Medicines by 15.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,195 shares of the company’s stock worth $265,000 after acquiring an additional 974 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its stake in Revolution Medicines by 4.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 28,904 shares of the company’s stock worth $1,063,000 after purchasing an additional 1,300 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Trading Up 1.4%

Shares of Revolution Medicines stock opened at $97.49 on Monday. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16. The company has a fifty day simple moving average of $92.51 and a 200-day simple moving average of $64.13. The stock has a market cap of $18.85 billion, a price-to-earnings ratio of -18.86 and a beta of 1.01. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $124.49.

Analysts Set New Price Targets

Several research analysts have commented on RVMD shares. Raymond James Financial boosted their price target on shares of Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a report on Friday, October 17th. Mizuho began coverage on shares of Revolution Medicines in a research report on Tuesday, October 21st. They set an “outperform” rating and a $90.00 price objective for the company. National Bankshares set a $80.00 target price on shares of Revolution Medicines in a research note on Friday, October 17th. UBS Group raised Revolution Medicines to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Wolfe Research assumed coverage on Revolution Medicines in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 price target on the stock. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $78.94.

Insider Transactions at Revolution Medicines

In related news, COO Margaret A. Horn sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $100.56, for a total transaction of $7,542,000.00. Following the transaction, the chief operating officer owned 141,053 shares in the company, valued at $14,184,289.68. This trade represents a 34.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the transaction, the chief financial officer directly owned 108,065 shares in the company, valued at approximately $10,590,370. This trade represents a 8.47% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 213,792 shares of company stock worth $17,948,440. 8.20% of the stock is owned by company insiders.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.